Internal Medicine, Pulmonary Disease · New Haven, CT
NPI
1679660021
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
46 Prince St, Suite 306
New Haven, CT, 06519
Phone (203) 786-5067
Groups this clinician bills Medicare through
Medicare paid, 2024
$348K
4,129 services
Medicare patients, 2024
683
Average age 74
Drug cost, 2024
$5.8M
6,283 prescriptions
Company payments, 2025
$60K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael A Imevbore was code 99214 (office e&m - established), 1,147 times for 571 patients. In total Michael A Imevbore billed 4,129 services in 42 codes, and Medicare paid $348K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,147 | 571 | $106.12 | $122K |
| 94010 Pulmonary Function Testing | Office | 517 | 443 | $23.71 | $12K |
| 94727 Pulmonary Function Testing | Office | 517 | 443 | $38.45 | $20K |
| 94729 Pulmonary Function Testing | Office | 517 | 443 | $48.69 | $25K |
| 94660 Treatment - Miscellaneous | Office | 298 | 120 | $52.12 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 233 | 47 | $99.52 | $23K |
| 96401 Chemotherapy Administration | Office | 114 | 21 | $62.55 | $7,131 |
| 94664 E&M - Miscellaneous | Office | 109 | 98 | $15.87 | $1,730 |
| 99291 Critical Care E&M | Facility | 99 | 23 | $177.96 | $18K |
| 99204 Office E&M - New | Office | 98 | 98 | $135.50 | $13K |
| 99407 Behavioral Health Services | Office | 80 | 51 | $29.09 | $2,327 |
| 94618 Pulmonary Function Testing | Office | 62 | 51 | $28.69 | $1,778 |
| 95810 Sleep Study | Office | 60 | 56 | $530.90 | $32K |
| 95811 Sleep Study | Office | 50 | 46 | $561.71 | $28K |
| 90732 Vaccine Product | Office | 26 | 24 | $129.52 | $3,368 |
By year: 2022 $382K for 4,585 services; 2023 $420K for 4,925 services; 2024 $348K for 4,129 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael A Imevbore prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,541 prescriptions and refills. In total Michael A Imevbore wrote 6,283 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,541 | 2,951 | 443 | $1.9M |
| Albuterol Sulfate Hfa Albuterol Sulfate | 832 | 902 | 297 | $17K |
| Montelukast Sodium Generic | 723 | 1,851 | 254 | $7,908 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 310 | 568 | 89 | $264K |
| Prednisone Generic | 285 | 426 | 164 | $1,218 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 269 | 549 | 108 | $345K |
| Pantoprazole Sodium Generic | 242 | 510 | 90 | $2,743 |
| Fasenra Benralizumab | 180 | 285 | 41 | $1.1M |
| Breo Ellipta Fluticasone/Vilanterol | 147 | 222 | 44 | $89K |
| Xolair Omalizumab | 98 | 103 | Under 11 | $350K |
| Ventolin Hfa Albuterol Sulfate | 97 | 105 | 44 | $6,040 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 91 | 143 | 42 | $17K |
| Symbicort Budesonide/Formoterol Fumarate | 81 | 153 | 38 | $35K |
| Roflumilast Generic | 80 | 147 | 19 | $6,750 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 72 | 100 | 24 | $6,191 |
Brand drugs: 3,840 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael A Imevbore $60K ($60K in general payments such as food, travel and fees) from 9 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $40K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 68 | $40K |
| Genzyme Corporation SNY | 17 | $18K |
| GlaxoSmithKline, LLC. GSK | 27 | $280 |
| Inspire Medical Systems, Inc. INSP | 7 | $144 |
| Amgen Inc. AMGN | 3 | $76.28 |
| Lilly USA, LLC LLY | 2 | $60.62 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23.7 |
| Insmed, Inc. INSM | 1 | $23.64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20.07 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.